Back to mobile site

Emergent BioSolutions (EBS) Misses Q4 EPS by 81c

February 26, 2026 4:59 PM EST

Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.43), $0.81 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $148.7 million versus the consensus estimate of $237 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings, Maynard Um, Mark Zuckerberg, ARK